Here are six new drug shortages and discontinuations, according to drug supply databases from the FDA and the American Society of Health-System Pharmacists.
Acetazolamide injection: Avet Pharmaceuticals and Hikma have reported a shortage of its 500-milligram, 1-count vials of acetazolamide sodium lyophilized powder for injection. Avet did not provide a reason for shortage and Hikma has the injection on allocation.
Desonide lotion: Actavis Pharma has discontinued manufacturing of its 0.5-milligram/1-milliliter presentation of Desown lotion, a topical corticosteroid used in dermatology to treat several skin conditions that involve inflammation, redness, itching or swelling.
Fluphenazine hydrochloride tablet: Upsher-Smith Laboratories has discontinued manufacturing of its 1-, 2.5-, 5- and 10-milligram fluphenazine hydrochloride tablets, an antipsychotic medication used to treat schizophrenia and other psychotic disorders.
Ibandronate sodium injection: Apotex and Eugi have reported a shortage of its 1-milligram/milliliter and 3-milliliter prefilled syringe of Ibandronate sodium intravenous solution. The drugmakers did not provide a reason for the shortage. Apotex has the presentations on backorder with an estimated release date of mid-November 2025. Eugia has the syringes on intermittent backorder and will be releasing supplies as they become available.
Obeticholic acid tablet: Intercept Pharmaceuticals has discontinued its 5- and 10-milligram Ocaliva tablet, a medication used to treat primary biliary cholangitis, a chronic liver disease. The shortage is due to a business decision.
Pilocarpine hydrochloride tablet: Actavis Pharma has discontinued the manufacturing of its 5- and 7.5-milligram Salagen tablets, a drug primarily used to treat symptoms of dry mouth for Sjogren’s disease or dry mouth following radiation therapy for neck or throat cancers.
The post 6 drugs in shortage appeared first on Becker's Hospital Review | Healthcare News & Analysis.
